Resistance

Resistance to raltegravir has been observed more frequently after viral rebound in treatment-experienced people than in those experiencing failure of their first antiretroviral regimen.1 2

A study of US patients with resistance to either raltegravir or elvitegravir predicted that based on the observed mutation patterns, approximately 12% would have high-level resistance to dolutegravir.3

References

  1. Hazuda DJ et al. Analysis of resistance to the HIV-1 integrase inhibitor raltegravir: results from the Benchmrk 1 and 2. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, abstract H-898, 2008
  2. Cooper DA et al. Subgroup and resistance analysis of raltegravir for resistant HIV-1 infection. N Engl J Med 359(4): 355-365, 2008
  3. Hurt CB et al. Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012. Clin Infect Dis 58: 423-31, 2014
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.